Gambini G, Rossi S, Valori C
Instituto di Patologia Speciale Medica e Metodologia Clinica, Università di Perugia, Terni, Italy.
Eur Heart J. 1991 Apr;12(4):550-3. doi: 10.1093/oxfordjournals.eurheartj.a059937.
The anti-hypertensive effect of ketanserin, a new antagonist of 5-HT2-serotonergic receptors, was evaluated in 10 patients with uncomplicated essential hypertension. At the end of 2 weeks of placebo wash-out and following 2 and 4 weeks of treatment with ketanserin (20 mg twice daily), blood pressure and heart rate were measured both in the supine and standing position. In addition, before and at the end of treatment, plasma renin activity (PRA), plasma concentration of aldosterone and the nocturnal urinary excretion of 6-keto-PGF1 alpha and TXB2, the two metabolites that largely reflect the renal synthesis of prostacyclin and thromboxane, respectively, were determined. The study was carried out in a metabolic ward where the intake of sodium was adjusted to 100-120 mmol day-1. Ketanserin significantly reduced blood pressure both in the supine and standing position with no significant change of heart rate. The treatment did not produce any variation of PRA, aldosterone, urinary excretion of 6-keto-PGF1 alpha or TXB2. These results indicate that ketanserin reduces blood pressure without interfering with the renin-angiotensin-aldosterone system or the renal synthesis of prostacyclin and thromboxane.
对10例单纯性原发性高血压患者评估了新型5-HT2-血清素能受体拮抗剂酮色林的降压效果。在2周安慰剂洗脱期结束后，以及用酮色林（每日2次，每次20mg）治疗2周和4周后，测量仰卧位和站立位的血压及心率。此外，在治疗前和治疗结束时，测定血浆肾素活性（PRA）、醛固酮血浆浓度以及6-酮-前列环素F1α和血栓素B2的夜间尿排泄量，这两种代谢产物分别很大程度上反映了前列环素和血栓素的肾脏合成情况。该研究在一个代谢病房进行，钠摄入量调整为100 - 120mmol/天。酮色林使仰卧位和站立位血压均显著降低，心率无明显变化。治疗未使PRA、醛固酮、6-酮-前列环素F1α尿排泄量或血栓素B2发生任何改变。这些结果表明，酮色林降低血压而不干扰肾素-血管紧张素-醛固酮系统或前列环素和血栓素的肾脏合成。
